FABINO ENTERPRISES LIMITED

BSE: FABINO543444ISIN INE0DRT01018

Healthcare
Pharmaceuticals

Share price

₹20.31+0.96 (+4.96%)

as of 27 Apr 2026

52W high: ₹38.96
52W low: ₹13.01
Off 52W high: -47.87%
1M return: +38.16%
3M return: +39.11%
6M return: -11.70%
1Y return: -23.36%
20D avg volume: 32,550
50 DMA: ₹21.40
200 DMA: —

Key ratios Consolidated

Market cap: ₹4.27 Cr
Current price: ₹20.31
52W high / low: ₹38.96 / ₹13.01
Face value: ₹10.00
P/E: —
P/B: —
EPS (TTM): —
Book value / share: —
ROE: —
ROCE: -11.60%
Operating margin: —
Net margin: —
Debt / equity: —
Net debt: —
Interest cover: -4.69
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 18.4 days

Financials

Metric	FY26	FY25	FY24
Income statement
	20.84	18.04	—
	1.56	0.29	—
	23.14	18.14	—
	1.24	0.00	—
	20.07	16.36	—
	0.14	0.28	—
	0.13	0.13	—
	1.32	1.16	—
	-0.74	0.19	—
	-0.18	0.13	—
	-0.56	0.06	—
	-2.66	0.29	—
Key metrics
	-0.61	0.32	—
	-2.90%	1.80%	—
	-2.70%	0.30%	—
	-11.60%	5.30%	—
	15.50%	—	—
	-1,033.30%	—	—
	0.18	-0.17	—
	-0.34	2.00	—
	18.4	79.9	—
Balance sheet
	22.14	17.66	—
	21.54	17.03	—
	0.20	0.24	—
	16.46	14.17	—
	1.06	1.20	—
	3.67	0.00	—
	0.37	0.55	—
	16.47	11.42	—
	16.87	11.66	—
Cash flow
	0.19	0.12	—
	0.07	-0.42	—
	-0.30	0.48	—
	0.01	0.29	—

Metric	FY26	FY25	FY24
Income statement
	11.43	18.04	—
	1.30	0.29	—
	13.21	18.07	—
	0.00	0.00	—
	11.56	16.36	—
	0.13	0.27	—
	0.13	0.13	—
	1.02	1.11	—
	-0.48	0.26	—
	-0.12	0.13	—
	-0.36	0.13	—
	-1.71	0.63	—
Key metrics
	-0.35	0.39	—
	-3.10%	2.20%	—
	-3.10%	0.70%	—
	-6.90%	6.60%	—
	-36.60%	—	—
	-376.90%	—	—
	0.58	-0.41	—
	-1.64	-0.92	—
	22.3	62.3	—
Balance sheet
	17.32	13.01	—
	16.73	12.42	—
	1.05	0.22	—
	0.16	8.75	—
	12.68	1.20	—
	1.91	0.00	—
	0.37	0.46	—
	12.14	6.87	—
	12.28	7.11	—
Cash flow
	0.59	-0.12	—
	-0.01	-0.41	—
	-0.63	0.73	—
	0.01	0.29	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY (TTM)	Profit YoY (TTM)	1Y return
Sun Pharmaceutical Industries Ltd.	4,41,467	1,840.00	36.43	17.90%	+11.41%	+16.54%	+15.97%
Divi's Laboratories Ltd.	2,53,031	9,531.50	86.51	19.00%	+16.35%	+26.84%	+67.50%
Torrent Pharmaceuticals Ltd.	1,85,210	4,869.40	85.91	9.10%	+32.85%	+7.69%	+36.65%
Zydus Lifesciences Limited	1,20,897	1,212.00	26.32	19.20%	+21.11%	-2.51%	+24.17%
Cipla Ltd.	1,12,203	1,388.90	33.44	14.90%	+1.85%	-37.69%	-7.34%
Laurus Labs Limited	1,08,711	2,012.00	99.67	19.70%	+22.62%	+114.95%	+141.62%
Dr. Reddy's Laboratories Ltd.	1,02,035	1,222.50	32.05	13.90%	-0.87%	-44.57%	-2.41%
Mankind Pharma Limited	1,00,764	2,439.55	48.73	13.70%	+13.75%	+8.10%	-1.69%
Aurobindo Pharma Ltd.	97,814	1,700.00	26.36	13.60%	+9.09%	+9.48%	+55.88%
Lupin Ltd	94,286	2,061.85	16.98	28.40%	+28.19%	+49.13%	+7.35%
Glenmark Pharmaceuticals ltd	65,928	2,336.00	36.67	16.20%	+32.94%	+138.48%	+18.56%
Alkem Laboratories Limited	61,804	5,169.10	28.04	18.80%	+13.36%	-5.52%	-4.73%
Biocon Ltd.	61,114	375.00	146.77	2.90%	+9.83%	-36.60%	+10.62%
Abbott India Ltd. S	56,861	26,758.85	35.22	41.90%	+6.29%	+11.18%	-10.07%
GlaxoSmithkline Pharmaceuticals Ltd.	49,091	2,897.85	45.96	55.40%	+5.75%	+12.41%	+8.51%
Ipca Laboratories Ltd.	48,704	1,920.05	35.42	16.40%	+10.59%	+67.91%	+40.09%
Gland Pharma Limited	47,779	2,895.50	42.31	13.70%	+17.57%	+46.55%	+47.68%
Ajanta Pharma Ltd.	44,118	3,530.60	38.87	29.40%	+20.19%	+22.04%	+43.30%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87%	+7.56%	+45.79%
Emcure Pharmaceuticals Limited	36,534	1,925.75	35.85	25.10%	+18.36%	+32.39%	+49.95%
Wockhardt Ltd	35,539	2,187.20	85.85	6.40%	+18.37%	+377.85%	+63.78%
Sai Life Sciences Limited	33,566	1,580.35	92.74	18.10%	—	—	+84.38%
Neuland Laboratories Limited.	27,498	21,433.15	55.24	23.10%	+78.33%	+182.59%	+53.59%
PIRAMAL PHARMA LIMITED	27,486	206.45	-87.64	0.80%	+0.78%	-419.79%	+9.96%
ACUTAAS CHEMICALS LIMITED	26,308	3,213.30	67.92	27.70%	+40.91%	+104.14%	+136.27%
FABINO ENTERPRISES LIMITED	4	20.31	—	-11.60%	—	—	-23.36%

Filings & corporate actions

Recent announcements

Intimation for closure of trading window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication6 Sep 2026 · Company Update / Newspaper Publication
Intimation of Book Closure for 15th AGM4 Sep 2026 · Corp. Action / Book Closure
Annual Report of the Company for the Financial Year 2025-26 along with Notice of the Fifteenth Annual General Meeting4 Sep 2026 · Others / Reg. 34 (1) Annual Report
Notice of 15th AGM to be held onTuesday, September 29, 20264 Sep 2026 · AGM/EGM / AGM
1. Re-appointment of Mrs. Tesu Alakh (DIN : 07300250 as a Non Executive Indeppendent Director of the company . 2. Re-appointment of M/s. DGMS and co. Chartered Accounts, ( Firm Registration ....4 Sep 2026 · Company Update / Change in Management
Outcome of Board Meeting held on Friday, September 04, 2026.4 Sep 2026 · Others / Outcome without intimation
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Newspaper Cutting of the Post Offer Advertisement, which is published on July 22, 2026 in the newspapers ....22 Jul 2026 · Company Update / General
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 202616 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Appointment of Mrs. Shipra Rathi as the Company Secretary and Compliance Officer of the Company.16 Jul 2026 · Company Update / Change in Management
Appointment of Mrs. Shipra Rathi as the Company Secretary & Compliance Officer as well as key Managerial Personnel of the Company.16 Jul 2026 · Others / Outcome without intimation
Intimation of Resignation of Mr. Anand Katarmal as Company Secretary and Compliance officer of the company7 Jul 2026 · Company Update / Change in Management
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Newspaper Cutting of the Pre-Offer Advertisement, which is published on June 25, 2026 in the Newspapers ....25 Jun 2026 · Company Update / General
Announcement under Regulation 30 (LODR)-Newspaper Publication24 Jun 2026 · Company Update / Newspaper Publication
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer to the Equity Shareholders of Fabino Enterprises Ltd ("Target Company").17 Jun 2026 · Company Update / General
Results For The Financial Year Ended March 31, 202623 May 2026 · Result / Financial Results
1. The Audited Standalone Financial Results set out in compliance with Accounting Standards for the Half year and year ended March 31, 2026 together with Statement of Assets & Liabilities ....23 May 2026 · Board Meeting / Outcome of Board Meeting
Fabino Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 ,inter alia, to consider and approve 1. The Audited Financial ....20 May 2026 · Board Meeting / Board Meeting
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Draft Letter of Offer to the Equity Shareholders of Fabino Enterprises Ltd ("Target Company").13 May 2026 · Company Update / General
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Detailed Public Statement for the attention of the Equity Shareholders of Fabino Enterprises Ltd ("Target ....6 May 2026 · Company Update / General
Aryaman Financial Services Ltd ("Manager to the Offer") has submitted to BSE a copy of Public Announcement under Regulations 3(1) and 4 read with Regulations 13(1), 14 and 15(1) of Securities ....28 Apr 2026 · Company Update / Open Offer
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....11 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 201811 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sushma Shekhar10 Apr 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Intimation of Closure of Trading Window24 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 202514 Jan 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Resignation of Mr. Kuldeep Solanki (DIN: 07109951) as a Non-Executive Independent Director of the Company.26 Dec 2025 · Company Update / Resignation of Director
Intimation of Appointment of Additional Non-Executive Independent Director of Company26 Dec 2025 · Company Update / Change in Management
1. Appointment of Mrs. Deepali Singla (DIN: 11442242) as Additional (Non-Executive) designated as Independent Director subject to approval of shareholders of the Company. 2. Acceptance ....26 Dec 2025 · Others / Outcome without intimation
Results- Financial results for the Half Year ended September 30, 202513 Nov 2025 · Result / Financial Results
1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2025 together with Statement of Assets and Liabilities ....13 Nov 2025 · Board Meeting / Outcome of Board Meeting
Fabino Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve the Unaudited Financial ....10 Nov 2025 · Board Meeting / Board Meeting
Certificate Under Regulation 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 202514 Oct 2025 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation for the Closure of Trading Window25 Sep 2025 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer Report and Voting Results for the 14th AGM24 Sep 2025 · AGM/EGM / AGM
Proceedings of the 14th Annual General Meeting of the Company.22 Sep 2025 · AGM/EGM / AGM
Newspaper clippings - Notice of 14th Annual General Meeting30 Aug 2025 · Company Update / Newspaper Publication
Intimation of Book Closure for 14th Annual General Meeting29 Aug 2025 · Corp. Action / Book Closure
Annual Report of the Company for the Financial Year 2024-25 along with Notice of the Fourteenth Annual General Meeting29 Aug 2025 · Others / Reg. 34 (1) Annual Report
Notice of 14th Annual General Meeting (AGM) to be held on Monday, September 22, 202529 Aug 2025 · AGM/EGM / AGM